[
  {
    "objectID": "pages/appraisals.html",
    "href": "pages/appraisals.html",
    "title": "NICE appraisals",
    "section": "",
    "text": "Plain english summary of the two related NICE appraisals",
    "crumbs": [
      "Context",
      "NICE appraisals"
    ]
  },
  {
    "objectID": "pages/publication.html",
    "href": "pages/publication.html",
    "title": "Publication",
    "section": "",
    "text": "The development of this model was discussed in Lee et al.¬†2024. [1] This article is licensed under a CC-BY-NC-4.0 license, which enables us to share it below:\n\n\nA correction to the article was later published [2] and likewise shared below:\n\n\n\n\n\n\nReferences\n\n[1] Lee D, Burns D, Wilson E. NICE‚Äôs Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - Open 2024. https://doi.org/10.1007/s41669-024-00490-x.\n\n\n[2] Lee D, Burns D, Wilson E. Correction: NICE‚Äôs Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - Open 2024. https://doi.org/10.1007/s41669-024-00499-2.",
    "crumbs": [
      "Context",
      "Publication"
    ]
  },
  {
    "objectID": "pages/citation.html",
    "href": "pages/citation.html",
    "title": "Citation",
    "section": "",
    "text": "If you re-use this model please appropriately credit PenTAG for the work and refer to it as the Exeter Oncology Model: RCC edition. You can use the following citation:\n\nLee D., Muthukumar M., Lovell A., Farmer C., Burns D., Matthews J., Coelho H., O‚ÄôToole B., Trigg L., Snowsill T., Barnish M., Nikoglou T., Brand A., Ahmad Z., Abdelsabour A., Robinson S., Wilson E., Melendez-Torres G. Exeter Oncology Model: RCC edition URL: https://github.com/nice-digital/NICE-model-repo",
    "crumbs": [
      "Citation"
    ]
  },
  {
    "objectID": "pages/citation.html#how-to-cite-this-model",
    "href": "pages/citation.html#how-to-cite-this-model",
    "title": "Citation",
    "section": "",
    "text": "If you re-use this model please appropriately credit PenTAG for the work and refer to it as the Exeter Oncology Model: RCC edition. You can use the following citation:\n\nLee D., Muthukumar M., Lovell A., Farmer C., Burns D., Matthews J., Coelho H., O‚ÄôToole B., Trigg L., Snowsill T., Barnish M., Nikoglou T., Brand A., Ahmad Z., Abdelsabour A., Robinson S., Wilson E., Melendez-Torres G. Exeter Oncology Model: RCC edition URL: https://github.com/nice-digital/NICE-model-repo",
    "crumbs": [
      "Citation"
    ]
  },
  {
    "objectID": "pages/citation.html#acknowledgements",
    "href": "pages/citation.html#acknowledgements",
    "title": "Citation",
    "section": "Acknowledgements",
    "text": "Acknowledgements\n\nThis modified repository was developed by Amy Heather .",
    "crumbs": [
      "Citation"
    ]
  },
  {
    "objectID": "pages/acronyms.html",
    "href": "pages/acronyms.html",
    "title": "Acryonyms",
    "section": "",
    "text": "Acronym\nMeaning\n\n\n\n\n1L\nFirst line\n\n\n2L\nSecond line\n\n\n3L\nThird line\n\n\n4L\nFourth line\n\n\nAbs\nAbsolute\n\n\nACIC\nAcademic and commercial in confidence\n\n\nAE\nAdverse event\n\n\nASCO\nAmerican Society Of Clinical Oncology\n\n\naRCC\nAdvanced renal cell carcinoma\n\n\nAUC\nArea under the curve\n\n\nBSC\nBest supportive care\n\n\ncabo\ncabozantinib\n\n\nCIC\nCommercial in confidence\n\n\nCDF\nCancer Drugs Fund\n\n\nCE\nCost effectiveness\n\n\nCODA\nConvergence diagnostic and output analysis\n\n\ncPAS\nConfident patient access scheme\n\n\nDSU\nDecision support unit\n\n\nEAG\nExternal assessment group\n\n\nEOL\nEnd of life\n\n\nevero\nEverolimus\n\n\nFAD\nFinal appraisal document\n\n\nfav\nFavourable\n\n\nFP\nFractional polynomial\n\n\nGen\ngeneral\n\n\nHFS\nHand-foot syndrome\n\n\nHR\nHazard ratio\n\n\nHRQL\nHealth-related quality of life\n\n\nICER\nIncremental Cost-Effectiveness Ratio\n\n\nint\nIntermediate\n\n\nIO\nImmune-oncology\n\n\nIPD\nIndividual patient data\n\n\nipi\nIpilimumab\n\n\nIV\nIntravenous\n\n\nKM\nKaplan-Meier\n\n\nlenv\nLenvatinib\n\n\nLY\nLife year(s)\n\n\nLYG\nLife year(s) gained\n\n\nMRU\nMedical Resource Use\n\n\nNHSE\nNHS England\n\n\nNICE\nNational Institute For Health And Care Excellence\n\n\nnivo\nNivolumab\n\n\nNMA\nNetwork meta-analysis\n\n\nOS\nOverall survival\n\n\nPartSA\nnot sure\n\n\nPAS\nPatient access scheme\n\n\nPATT\nProportionate approach to technology appraisals\n\n\npazo\npazopanib\n\n\nPD\nProgressed disease\n\n\npem\nPembrolizumab\n\n\nPFS\nProgression-free survival\n\n\nPH\nProportional hazards\n\n\npop\nPopulation\n\n\nPPS\nPost-progression survival\n\n\nprop\nProportional\n\n\nQALY\nQuality-adjusted life year(s)\n\n\nQC\nQuality check\n\n\nRCC\nRenal cell carcinoma\n\n\nRDI\nRelative dosing intensity\n\n\nRWE\nReal-world evidence\n\n\nSF\nShortfall\n\n\nSOC\nStandard of care\n\n\nsuni\nSunitinib\n\n\nTA\nTechnology appraisal\n\n\ntivo\nTivozanib\n\n\nTKI\nTyrosine Kinase Inhibitor\n\n\nTP matrices\nTreatment pathway matrices\n\n\nTTD\nTime to discontinuation\n\n\nTTNT\nTime to next treatment\n\n\nTTP\nTime to progression\n\n\nUK\nUnited Kingdom\n\n\nvs\nVersus\n\n\nWTP\nWillingness to pay",
    "crumbs": [
      "Acryonyms"
    ]
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Exeter Oncology Model: Renal Cell Carcinoma edition",
    "section": "",
    "text": "The Exeter Oncology Model: Renal Cell Carcinoma edition (EOM:RCC) is a platform cost-effectiveness model encompassing each decision node in the disease area for advanced renal cell carcinoma.\nIt has been constructed as part of the National Institute for Health and Care Excellence (NICE) Pathways Pilot appraisal (ID6186, GID-TA11186) [1] and the appraisal of cabozantinib plus nivolumab (TA964) [2] (formerly ID6184, whilst in development).\nThe Pathways Pilot aims both at reducing the long-term resource requirements for appraisal within crowded treatment pathways and at assessing the feasibility of incorporating treatment sequences into decision making. The development of this model is described in Lee et al.¬†2024. [3]\nThis website provides ‚Ä¶\n\n\n\n\nReferences\n\n[1] National Institute for Health and Care Excellence (NICE). Renal cell carcinoma Pathways Pilot [ID6186]. In development [GID-TA11186] n.d.\n\n\n[2] National Institute for Health and Care Excellence (NICE). Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. Technology appraisal guidance [TA964] n.d.\n\n\n[3] Lee D, Burns D, Wilson E. NICE‚Äôs Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - Open 2024. https://doi.org/10.1007/s41669-024-00490-x.",
    "crumbs": [
      "Home"
    ]
  },
  {
    "objectID": "pages/changelog.html",
    "href": "pages/changelog.html",
    "title": "CHANGELOG",
    "section": "",
    "text": "All notable changes to this project will be documented in this file.\nThe format is based on Keep a Changelog, and this project adheres to Semantic Versioning. Dates formatted as YYYY-MM-DD as per ISO standard.\n\n\nEmbellished READMAE\n\n\n\nAdd files produced by model run to .gitignore\n\n\n\n\n\nExtended README.md to include banner image with logos, extra badges, table of contents, all the information from ID6184 Using the R decision model.. (e.g.¬†installation guide with images, overview of input files, future versions)\n\n\n\n\n\nImplemented the essential components of the STARS framework (exc. open science archive).\n\n\n\nCITATION.cff and GitHub action to check validity (cff_validation.yaml)\n\n\n\n\n\nExtended README.md to include some instructions for installing and running the model, more detailed repositoriy overview, citation information, ORCID IDs, acknowledgements, license and funding information\n\n\n\n\n\nFormatting of copyright statement in LICENSE\n\n\n\n\n\nüå± First release. EOM-RCC model as shared by the PenTAG team, with minor changes that enabled us to run the model.\n\n\n\nCode from the original repository - https://github.com/nice-digital/NICE-model-repo\nR environment for dependency management (renv)\n\n\n\n\n\nSet model to run sequentially (in 2_Scripts/Model_Structure.R)",
    "crumbs": [
      "Changelog"
    ]
  },
  {
    "objectID": "pages/changelog.html#v1.1.1---2024-08-20",
    "href": "pages/changelog.html#v1.1.1---2024-08-20",
    "title": "CHANGELOG",
    "section": "",
    "text": "Embellished READMAE\n\n\n\nAdd files produced by model run to .gitignore\n\n\n\n\n\nExtended README.md to include banner image with logos, extra badges, table of contents, all the information from ID6184 Using the R decision model.. (e.g.¬†installation guide with images, overview of input files, future versions)",
    "crumbs": [
      "Changelog"
    ]
  },
  {
    "objectID": "pages/changelog.html#v1.1.0---2024-08-16",
    "href": "pages/changelog.html#v1.1.0---2024-08-16",
    "title": "CHANGELOG",
    "section": "",
    "text": "Implemented the essential components of the STARS framework (exc. open science archive).\n\n\n\nCITATION.cff and GitHub action to check validity (cff_validation.yaml)\n\n\n\n\n\nExtended README.md to include some instructions for installing and running the model, more detailed repositoriy overview, citation information, ORCID IDs, acknowledgements, license and funding information\n\n\n\n\n\nFormatting of copyright statement in LICENSE",
    "crumbs": [
      "Changelog"
    ]
  },
  {
    "objectID": "pages/changelog.html#v1.0.0---2024-08-16",
    "href": "pages/changelog.html#v1.0.0---2024-08-16",
    "title": "CHANGELOG",
    "section": "",
    "text": "üå± First release. EOM-RCC model as shared by the PenTAG team, with minor changes that enabled us to run the model.\n\n\n\nCode from the original repository - https://github.com/nice-digital/NICE-model-repo\nR environment for dependency management (renv)\n\n\n\n\n\nSet model to run sequentially (in 2_Scripts/Model_Structure.R)",
    "crumbs": [
      "Changelog"
    ]
  },
  {
    "objectID": "pages/license.html",
    "href": "pages/license.html",
    "title": "License",
    "section": "",
    "text": "This repository is licensed under an MIT license:\n\n\n\n\n\n\nMIT License\nCopyright (c) 2024 University of Exeter, Exeter Oncology Model; RCC edition\nPermission is hereby granted, free of charge, to any person obtaining a copy of this model and associated documentation files (the ‚ÄúRCC Model‚Äù), to deal in the RCC Model without restriction, including without limitation the rights to use, copy, modify, merge, publish, distribute, sublicense, and/or sell copies of the RCC Model, and to permit persons to whom the RCC Model is furnished to do so, subject to the following conditions:\nThe above copyright notice and this permission notice shall be included in all copies or substantial portions of the RCC Model.\nTHE RCC MODEL IS PROVIDED ‚ÄúAS IS‚Äù, WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE RCC MODEL.",
    "crumbs": [
      "License"
    ]
  },
  {
    "objectID": "pages/plain_english.html",
    "href": "pages/plain_english.html",
    "title": "Model",
    "section": "",
    "text": "Plain english summary of model.",
    "crumbs": [
      "Context",
      "Model plain english summary"
    ]
  }
]